CoChat
Sign Up
Cited by 139Glycosylation and Glycoproteins ResearchAlzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration Mechanisms

O -GlcNAcylation ameliorates the pathological manifestations of Alzheimer’s disease by inhibiting necroptosis

Open access
Park, Jinsu, Ha, Hee-Jin, Chung, Eun Seon, Baek, Seung Hyun, Cho, Yoonsuk, Kim, Hark Kyun, Han, Jihoon, Sul, Jae Hoon +11 more·2021·Science Advances
DOI 10.1126/sciadv.abd3207PMC PMC7806231
Open this paper in CoChat — free account

Abstract

Increased O -GlcNAcylation can confer neuroprotective effects against necroptosis in the context of Alzheimer’s disease.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1126/sciadv.abd3207

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 41

  1. [1]Wang J., Gu B. J., Masters C. L., Wang Y.-J., A systemic view of Alzheimer disease—Insights from amyloid-β metabolism beyond the brain. Nat. Rev. Neurol. 13, 612– 623 (2017). 28960209
  2. [2]Lee H., Kim D., Lee W., Kim H. Y., Kim Y., Preventive approach for overcoming dementia. Arch. Pharm. Res. 42, 647– 657 (2019). 31187441
  3. [3]Livingston G., Sommerlad A., Orgeta V., Costafreda S. G., Huntley J., Ames D., Ballard C., Banerjee S., Burns A., Cohen-Mansfield J., Cooper C., Fox N., Gitlin L. N., Howard R., Kales H. C., Larson E. B., Ritchie K., Rockwood K., Sampson E. L., Samus Q., Schneider L. S., Selbæk G., Teri L., Mukadam N., Dementia prevention, intervention, and care. Lancet 390, 2673– 2734 (2017). 28735855
  4. [4]Li Q., Barres B. A., Microglia and macrophages in brain homeostasis and disease. Nat. Rev. Immunol. 18, 225– 242 (2018). 29151590
  5. [5]Caccamo A., Branca C., Piras I. S., Ferreira E., Huentelman M. J., Liang W. S., Readhead B., Dudley J. T., Spangenberg E. E., Green K. N., Belfiore R., Winslow W., Oddo S., Necroptosis activation in Alzheimer’s disease. Nat. Neurosci. 20, 1236– 1246 (2017). 28758999
  6. [7]Rubinsztein D. C., RIPK1 promotes inflammation and β-amyloid accumulation in Alzheimer’s disease. Proc. Natl. Acad. Sci. U.S.A. 114, 10813– 10814 (2017). 28973950 PMC5642738
  7. [9]Yang S.-H., Lee D. K., Shin J., Lee S., Baek S., Kim J., Jung H., Hah J.-M., Kim Y., Nec-1 alleviates cognitive impairment with reduction of Aβ and tau abnormalities in APP/PS1 mice. EMBO Mol. Med. 9, 61– 77 (2016). PMC5210088 27861127
  8. [11]Ofengeim D., Ito Y., Najafov A., Zhang Y., Shan B., DeWitt J. P., Ye J., Zhang X., Chang A., Vakifahmetoglu-Norberg H., Geng J., Py B., Zhou W., Amin P., Berlink Lima J., Qi C., Yu Q., Trapp B., Yuan J., Activation of necroptosis in multiple sclerosis. Cell Rep. 10, 1836– 1849 (2015). 25801023 PMC4494996
  9. [13]Park J., Lai M. K. P., Arumugam T. V., Jo D.-G., O-GlcNAcylation as a therapeutic target for Alzheimer’s disease. Neuromol. Med. 22, 171– 193 (2020). 31894464
  10. [14]Lewis Y. E., Galesic A., Levine P. M., De Leon C. A., Lamiri N., Brennan C. K., Pratt M. R., O-GlcNAcylation of α-synuclein at serine 87 reduces aggregation without affecting membrane binding. ACS Chem. Biol. 12, 1020– 1027 (2017). 28195695 PMC5607117
  11. [16]Yuzwa S. A., Shan X., Macauley M. S., Clark T., Skorobogatko Y., Vosseller K., Vocadlo D. J., Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat. Chem. Biol. 8, 393– 399 (2012). 22366723
  12. [17]Gao Y., Wells L., Comer F. I., Parker G. J., Hart G. W., Dynamic O–glycosylation of nuclear and cytosolic proteins: Cloning and characterization of a neutral, cytosolic beta-N-acetylglucosaminidase from human brain. J. Biol. Chem. 276, 9838– 9845 (2001). 11148210
  13. [18]Yang Y. R., Song M., Lee H., Jeon Y., Choi E.-J., Jang H.-J., Moon H. Y., Byun H.-Y., Kim E.-K., Kim D. H., Lee M. N., Koh A., Ghim J., Choi J. H., Lee-Kwon W., Kim K. T., Ryu S. H., Suh P.-G., O-GlcNAcase is essential for embryonic development and maintenance of genomic stability. Aging Cell 11, 439– 448 (2012). 22314054
  14. [20]Liu F., Shi J., Tanimukai H., Gu J., Gu J., Grundke-Iqbal I., Iqbal K., Gong C.-X., Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer’s disease. Brain 132, 1820– 1832 (2009). 19451179 PMC2702834
  15. [21]Wang A. C., Jensen E. H., Rexach J. E., Vinters H. V., Hsieh-Wilson L. C., Loss of O-GlcNAc glycosylation in forebrain excitatory neurons induces neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 113, 15120– 15125 (2016). 27956640 PMC5206508
  16. [22]Yuzwa S. A., Shan X., Jones B. A., Zhao G., Woodward M. L., Li X., Zhu Y., McEachern E. J., Silverman M. A., Watson N. V., Gong C.-X., Vocadlo D. J., Pharmacological inhibition of O-GlcNAcase (OGA) prevents cognitive decline and amyloid plaque formation in bigenic tau/APP mutant mice. Mol. Neurodegener. 9, 42 (2014). 25344697 PMC4232697
  17. [23]Tan E. P., McGreal S. R., Graw S., Tessman R., Koppel S. J., Dhakal P., Zhang Z., Machacek M., Zachara N. E., Koestler D. C., Peterson K. R., Thyfault J. P., Swerdlow R. H., Krishnamurthy P., DiTacchio L., Apte U., Slawson C., Sustained O-GlcNAcylation reprograms mitochondrial function to regulate energy metabolism. J. Biol. Chem. 292, 14940– 14962 (2017). 28739801 PMC5592672
  18. [24]Cha M.-Y., Cho H. J., Kim C., Jung Y. O., Kang M. J., Murray M. E., Hong H. S., Choi Y.-J., Choi H., Kim D. K., Choi H., Kim J., Dickson D. W., Song H. K., Cho J. W., Yi E. C., Kim J., Jin S. M., Mook-Jung I., Mitochondrial ATP synthase activity is impaired by suppressed O-GlcNAcylation in Alzheimer’s disease. Hum. Mol. Genet. 24, 6492– 6504 (2015). 26358770 PMC5007609
  19. [25]Li J., McQuade T., Siemer A. B., Napetschnig J., Moriwaki K., Hsiao Y.-S., Damko E., Moquin D., Walz T., McDermott A., Chan F. K.-M., Wu H., The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell 150, 339– 350 (2012). 22817896 PMC3664196
  20. [26]Macauley M. S., Shan X., Yuzwa S. A., Gloster T. M., Vocadlo D. J., Elevation of global O-GlcNAc in rodents using a selective O-GlcNAcase inhibitor does not cause insulin resistance or perturb glucohomeostasis. Chem. Biol. 17, 949– 958 (2010). 20851344 PMC2954292
  21. [27]Keembiyehetty C., Love D. C., Harwood K. R., Gavrilova O., Comly M. E., Hanover J. A., Conditional knock-out reveals a requirement for O-linked N-acetylglucosaminase (O-GlcNAcase) in metabolic homeostasis. J. Biol. Chem. 290, 7097– 7113 (2015). 25596529 PMC4358131
  22. [31]Griffith L. S., Schmitz B., O-linked N-acetylglucosamine is upregulated in Alzheimer brains. Biochem. Biophys. Res. Commun. 213, 424– 431 (1995). 7646495
  23. [32]Förster S., Welleford A. S., Triplett J. C., Sultana R., Schmitz B., Butterfield D. A., Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim. Biophys. Acta 1842, 1333– 1339 (2014). 24859566 PMC4140188
  24. [33]Li X., Gong W., Wang H., Li T., Attri K. S., Lewis R. E., Kalil A. C., Bhinderwala F., Powers R., Yin G., Herring L. E., Asara J. M., Lei Y. L., Yang X., Rodriguez D. A., Yang M., Green D. R., Singh P. K., Wen H., O-GlcNAc transferase suppresses inflammation and necroptosis by targeting receptor-interacting serine/threonine-protein kinase 3. Immunity 50, 576– 590.e6 (2019). 30770249 PMC6426684
  25. [34]Zhang B., Li M.-D., Yin R., Liu Y., Yang Y., Mitchell-Richards K. A., Nam J. H., Li R., Wang L., Iwakiri Y., Chung D., Robert M. E., Ehrlich B. E., Bennett A. M., Yu J., Nathanson M. H., Yang X., O-GlcNAc transferase suppresses necroptosis and liver fibrosis. JCI Insight 4, 127709 (2019). 31672932 PMC6948774
  26. [35]Kim C., Nam D. W., Park S. Y., Hong H. S., Boo J. H., Jung E. S., Kim Y., Baek J. U., Kim K. S., Cho J. W., Mook-Jung I., O-linked β-N-acetylglucosaminidase inhibitor attenuates β-amyloid plaque and rescues memory impairment. Neurobiol. Aging 34, 275– 285 (2013). 22503002
  27. [36]Jacobsen K. T., Iverfeldt K., O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-β precursor protein (APP). Biochem. Biophys. Res. Commun. 404, 882– 886 (2011). 21182826
  28. [39]Pan R.-Y., Ma J., Kong X.-X., Wang X.-F., Li S.-S., Qi X.-L., Yan Y.-H., Cheng J., Liu Q., Jin W., Tan C.-H., Yuan Z., Sodium rutin ameliorates Alzheimer’s disease–like pathology by enhancing microglial amyloid-β clearance. Sci. Adv. 5, eaau6328 (2019). 30820451 PMC6393001
  29. [40]Ryu I.-H., Lee K.-Y., Do S.-I., Aβ-affected pathogenic induction of S-nitrosylation of OGT and identification of Cys-NO linkage triplet. Biochim. Biophys. Acta 1864, 609– 621 (2016). 26854602
  30. [41]Tramutola A., Sharma N., Barone E., Lanzillotta C., Castellani A., Lavarone F., Vincenzoni F., Castagnola M., Butterfield D. A., Gaetani S., Cassano T., Perluigi M., Di Domenico F., Proteomic identification of altered protein O-GlcNAcylation in a triple transgenic mouse model of Alzheimer’s disease. Biochim. Biophys. Acta Mol. Basis Dis. 1864, 3309– 3321 (2018). 30031227
  31. [42]Sandhu P., Lee J., Ballard J., Walker B., Ellis J., Marcus J., Toolan D., Dreyer D., McAvoy T., Duffy J., Michener M., Valiathan C., Trainor N., Savage M., McEachern E., Vocadlo D., Smith S. M., Struyk A., Pharmacokinetics and pharmacodynamics to support clinical studies of MK-8719: An O-GlcNAcase inhibitor for progressive supranuclear palsy. Alzheimers Dement. 12, P1028 (2016).
  32. [43]Ryan J. M., Quattropani A., Abd-Elaziz K., den Daas I., Schneider M., Ousson S., Neny M., Sand A., Hantson J., Permanne B., Wiessner C., Beher D., O1-12-05: Phase 1 study in healthy volunteers of the O-GlcNAcase inhibitor ASN120290 as a novel therapy for progressive supranuclear palsy and related tauopathies. Alzheimers Dement. 14, P251 (2018).
  33. [44]Hyman B. T., Trojanowski J. Q., Consensus recommendations for the post-mortem diagnosis of Alzheimer disease from the National Institute on Aging and the Reagan Institute Working Group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J. Neuropathol. Exp. Neurol. 56, 1095– 1097 (1997). 9329452
  34. [45]Bahn G., Park J.-S., Yun U. J., Lee Y. J., Choi Y., Park J. S., Baek S. H., Choi B. Y., Cho Y. S., Kim H. K., Han J., Sul J. H., Baik S.-H., Lim J., Wakabayashi N., Bae S. H., Han J.-W., Arumugam T. V., Mattson M. P., Jo D.-G., NRF2/ARE pathway negatively regulates BACE1 expression and ameliorates cognitive deficits in mouse Alzheimer’s models. Proc. Natl. Acad. Sci. U.S.A. 116, 12516– 12523 (2019). 31164420 PMC6589670
  35. [46]Gwon A.-R., Park J.-S., Arumugam T. V., Kwon Y.-K., Chan S. L., Kim S.-H., Baik S.-H., Yang S., Yun Y.-K., Choi Y., Kim S., Tang S.-C., Hyun D.-H., Cheng A., Dann C. E. III, Bernier M., Lee J., Markesbery W. R., Mattson M. P., Jo D.-G., Oxidative lipid modification of nicastrin enhances amyloidogenic γ-secretase activity in Alzheimer’s disease. Aging Cell 11, 559– 568 (2012). 22404891 PMC4217088
  36. [47]Baik S.-H., Fane M., Park J. H., Cheng Y.-L., Fann D. Y.-W., Yun U. J., Choi Y., Park J.-S., Chai B. H., Park J. S., Back S. H., Jeong J. I., Jang Y. J., Bahn G., Lee J.-Y., Li Y.-I., Sobey C. G., Uchida T., Park J. H., Kim H. T., Tang S.-C., Arumugam T. V., Jo D.-G., Pin1 promotes neuronal death in stroke by stabilizing Notch intracellular domain. Ann. Neurol. 77, 504– 516 (2015). 25558977
  37. [48]Kim H. Y., Lee D. K., Chung B.-R., Kim H. V., Kim Y., Intracerebroventricular injection of amyloid-β peptides in normal mice to acutely induce Alzheimer-like cognitive deficits. J. Vis. Exp. 109, e53308 (2016). PMC4829024 27023127
  38. [49]Park J., Madan M., Chigurupati S., Baek S. H., Cho Y., Mughal M. R., Yu A., Chan S. L., Pattisapu J. V., Mattson M. P., Jo D.-G., Neuronal Aquaporin 1 inhibits amyloidogenesis by suppressing the interaction between beta-secretase and amyloid precursor protein. J. Gerontol. A Biol. Sci. Med. Sci., glaa068 (2020). PMC7756701 32154567
  39. [50]Zhang L., Ren F., Li J., Ma X., Wang P., A modified coupled enzyme method for O-linked GlcNAc transferase activity assay. Biol. Proced. Online 11, 170– 183 (2009). 19957065 PMC3056017
  40. [51]He Y., Ma X., Li D., Hao J., Thiamet G mediates neuroprotection in experimental stroke by modulating microglia/macrophage polarization and inhibiting NF-κB p65 signaling. J. Cereb. Blood Flow Metab. 37, 2938– 2951 (2017). 27864466 PMC5536801
  41. [52]Rossi C., Cusimano M., Zambito M., Finardi A., Captondo A., Garcia-Manteiga J. M., Comi G., Furlan R., Martino G., Muzio L., Interleukin 4 modulates microglia homeostasis and attenuates the early slowly progressive phase of amyotrophic lateral sclerosis. Cell Death Dis. 9, 250 (2018). 29445154 PMC5833860

Cited by

Sorted by citations

Authors
Park, J., Ha, H.-J., Chung, E. S., Baek, S. H., Cho, Y., Kim, H. K., Han, J., Sul, J. H., Lee, J., Kim, E., Kim, J., Yang, Y. R., Park, M., Kim, S. H., Arumugam, T. V., Jang, H., Seo, S. W., Suh, P.-G., & Jo, D.-G.
Affiliations
  • Sungkyunkwan University (KR)
  • Tufts University (US)
  • Korea Research Institute of Bioscience and Biotechnology (KR)
  • Korea Institute of Science and Technology (KR)
  • Kyung Hee University (KR)
  • La Trobe University (AU)
  • Samsung Medical Center (KR)
  • Korea Brain Research Institute (KR)
Corresponding author
Jo, Dong-Gyu
ORCID
Venue
Science Advances
Publisher
American Association for the Advancement of Science (AAAS)
Published
2021-01-15
Volume
7
Issue
3
ISSN
2375-2548 (ISSN-L)
DOI
10.1126/sciadv.abd3207
PMC
PMC7806231
OpenAlex
W3119131078
Cited by
139
References
11
Citations by year
2026: 18 · 2025: 24 · 2024: 26 · 2023: 37 · 2022: 22 · 2021: 12
FWCI
7.92
Type
journal article
Language
en
Open access
Licence
Locations
  • Science Advances (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Figshare (submittedVersion, cc-by-nc)
  • La Trobe University
Funders
National Research Foundation of Korea
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
O-GlcNAcylation, Alzheimer's disease, necroptosis, neuroprotection, post-translational modification, neurodegeneration
MeSH terms
Necroptosis, Alzheimer Disease, Animals, Brain, Humans, Phosphorylation, Amyloid beta-Peptides, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review